Amanda Wilhelm
Overview
Explore the profile of Amanda Wilhelm including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
40
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frank S, Anderson K, Fernandez H, Hauser R, Claassen D, Stamler D, et al.
Neurol Ther
. 2024 Sep;
13(6):1747-1749.
PMID: 39266813
No abstract available.
2.
Frank S, Anderson K, Fernandez H, Hauser R, Claassen D, Stamler D, et al.
Neurol Ther
. 2024 Apr;
13(3):655-675.
PMID: 38557959
Introduction: Deutetrabenazine is a vesicular monoamine transporter 2 inhibitor used to treat tardive dyskinesia (TD) and chorea associated with Huntington disease (HD). To enhance detection of safety signals across individual...
3.
Robinson D, Suett M, Wilhelm A, Chaijale N, Franzenburg K, Gandhi S, et al.
Adv Ther
. 2023 Mar;
40(5):2249-2264.
PMID: 36905498
Introduction: Studies evaluating patient and healthcare professional (HCP) preferences regarding long-acting injectable (LAI) antipsychotic agent attributes are lacking. Methods: Surveys were administered to physicians, nurses, and patients who had at...
4.
Macfadden W, Wilhelm A, Candler S, Mettam S
Future Cardiol
. 2022 Nov;
18(12):921-923.
PMID: 36321776
No abstract available.
5.
Stacy S, Salinas G, Belcher E, Wilhelm A, Alexander J, Mattingly G
CNS Spectr
. 2022 Jul;
28(3):387.
PMID: 35791686
No abstract available.
6.
Hauser R, Barkay H, Wilhelm A, Wieman M, Savola J, Gordon M
Parkinsonism Relat Disord
. 2022 Mar;
97:47-51.
PMID: 35299070
Introduction: Deutetrabenazine is approved by the US Food and Drug Administration to treat tardive dyskinesia (TD) based on 2 pivotal, 12-week, placebo-controlled studies (ARM-TD and AIM-TD) evaluating safety and efficacy...
7.
Hauser R, Barkay H, Fernandez H, Factor S, Jimenez-Shahed J, Gross N, et al.
Front Neurol
. 2022 Mar;
13:773999.
PMID: 35280262
Background: Deutetrabenazine is a vesicular monoamine transporter 2 inhibitor approved for the treatment of tardive dyskinesia (TD) in adults. In two 12-week pivotal studies, deutetrabenazine demonstrated statistically significant improvements in...
8.
Stacy S, Salinas G, Belcher E, Wilhelm A, Alexander J, Mattingly G
CNS Spectr
. 2022 Feb;
28(3):343-350.
PMID: 35179458
Objective: To better understand current practices of U.S.-based physicians in the management of Tourette syndrome (TS) and identify gaps that may be addressed by future education. Methods: Two survey instruments...
9.
Rutigliano H, Thomas A, Umbaugh J, Wilhelm A, Sessions B, Kaundal R, et al.
Am J Reprod Immunol
. 2022 Jan;
87(3):e13520.
PMID: 34974639
Problem: A significant rate of spontaneous abortion is observed in cattle pregnancies produced by somatic cell nuclear transfer (SCNT). Major histocompatibility complex class I (MHC-I) proteins are abnormally expressed on...
10.
Clayton M, Kelly E, Mainenti M, Wilhelm A, Torchetti M, Killian M, et al.
J Vet Diagn Invest
. 2021 Oct;
34(1):82-85.
PMID: 34697977
Mink are susceptible to infection with influenza A virus (IAV) of swine and human origin. In 2019, a Utah mink farm had an outbreak of respiratory disease in kits caused...